Signaling Pathways of BAFF and APRIL in B-Cell Development: Relevance to ANCA-Associated Vasculitis Pathogenesis
-
By
-
Yasuhiro Shimojima
-
Shuhei Yoshida
-
Haruki Matsumoto
-
Yuya Sumichika
-
Tomoyuki Asano
-
Shuzo Sato
-
July 21, 2026
Clinical Scorecard: Signaling Pathways of BAFF and APRIL in B-Cell Development: Relevance to ANCA-Associated Vasculitis Pathogenesis
At a Glance
| Category | Detail |
|---|
| Condition | ANCA-Associated Vasculitis (AAV) |
| Key Mechanisms | Upregulated BAFF and APRIL signaling pathways contribute to autoreactive B cell activation and survival. |
| Target Population | Patients with ANCA-associated vasculitis, including MPA, GPA, and EGPA. |
| Care Setting | Clinical management of autoimmune diseases. |
Key Highlights
- B cells are crucial in AAV pathogenesis through ANCA production and cytokine secretion.
- BAFF and APRIL levels are elevated in AAV and associated with disease activity.
- Rituximab (RTX) is effective for B-cell depletion but requires repeated administration.
- Residual autoreactive B cells contribute to relapse after RTX withdrawal.
- Targeting BAFF/APRIL signaling may provide novel therapeutic strategies.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of AAV is based on clinical presentation and the presence of MPO-ANCA or PR3-ANCA.
Management
- Induction therapy may include cyclophosphamide and rituximab for remission.
Monitoring & Follow-up
- Monitor BAFF and APRIL levels as potential indicators of disease activity and relapse.
Risks
- Infection risk associated with B-cell depletion therapies like RTX.
Patient & Prescribing Data
Patients with active ANCA-associated vasculitis.
RTX is effective for inducing remission, but relapse is common post-therapy.
Clinical Best Practices
- Consider the role of autoreactive B cells in disease management.
- Evaluate BAFF/APRIL signaling as a therapeutic target.
Related Resources & Content
